Literature DB >> 24368236

Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.

Joanne M Harrington1, Dawn C Schwenke2, Dana R Epstein3, Donald E Bailey4.   

Abstract

PURPOSE/
OBJECTIVES: To examine the trajectory of changes in body composition and metabolic profile in men who receive androgen-deprivation therapy (ADT) for prostate cancer.
DESIGN: Prospective longitudinal design with repeated measures.
SETTING: Urban medical center in the southwestern United States. SAMPLE: 55 men starting radiation therapy for prostate cancer.
METHODS: Changes in the parameters of metabolic syndrome were estimated with ADT (n=31) and non-ADT (n=24) groups by repeated-measures analysis of variance implemented by general linear mixed-effects models. Models included interactions between groups and follow-up time to test differences between the groups. MAIN RESEARCH VARIABLES: Body composition and metabolic variables.
FINDINGS: The ADT group demonstrated a transient increase in waist circumference at the nine-month time point and significant changes in measures of insulin resistance were noted at the three month point. Values for diastolic and systolic blood pressure, plasma glucose, high-density lipoprotein, and triglycerides were not altered for either group. Differences in metabolic variables or measures of body composition did not differ significantly between the groups.
CONCLUSIONS: The findings demonstrate the development of insulin resistance in men receiving ADT as early as three months after starting ADT. IMPLICATIONS FOR NURSING: Addressing survivorship concerns can lead to the development of nursing interventions designed to reduce adverse effects associated with ADT.

Entities:  

Keywords:  androgen-deprivation therapy; metabolic syndrome; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24368236     DOI: 10.1188/14.ONF.21-29

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  8 in total

Review 1.  Metabolomic profiling of hormone-dependent cancers: a bird's eye view.

Authors:  Stacy M Lloyd; James Arnold; Arun Sreekumar
Journal:  Trends Endocrinol Metab       Date:  2015-08-01       Impact factor: 12.015

Review 2.  The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review.

Authors:  T Hasenoehrl; M Keilani; T Sedghi Komanadj; M Mickel; M Margreiter; M Marhold; R Crevenna
Journal:  Support Care Cancer       Date:  2015-05-24       Impact factor: 3.603

3.  Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide.

Authors:  Yi-Ting Lin; Yen-Chun Huang; Chih-Kuan Liu; Tian-Shyug Lee; Mingchih Chen; Yu-Ning Chien
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

Review 4.  Effects of resistance exercise in prostate cancer patients: a meta-analysis.

Authors:  M Keilani; T Hasenoehrl; L Baumann; R Ristl; M Schwarz; M Marhold; T Sedghi Komandj; R Crevenna
Journal:  Support Care Cancer       Date:  2017-06-10       Impact factor: 3.603

Review 5.  Metabolic Syndrome: conceptual analysis in the nursing context.

Authors:  Nuno Damácio de Carvalho Félix; Maria Miriam Lima da Nóbrega
Journal:  Rev Lat Am Enfermagem       Date:  2019-08-19

6.  The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a population-based cohort study.

Authors:  Hsiang-Wen Chien; Chiao-Wen Lin; Chia-Yi Lee; Jing-Yang Huang; Shun-Fa Yang; Kai Wang
Journal:  Int J Med Sci       Date:  2022-06-21       Impact factor: 3.642

Review 7.  Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome.

Authors:  I-Chen Yu; Hung-Yun Lin; Janet D Sparks; Shuyuan Yeh; Chawnshang Chang
Journal:  Diabetes       Date:  2014-10       Impact factor: 9.461

8.  Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patients.

Authors:  Vita Birzniece; Teresa Lam; Mark McLean; Navneeta Reddy; Haleh Shahidipour; Amy Hayden; Howard Gurney; Glenn Stone; Rikke Hjortebjerg; Jan Frystyk
Journal:  Endocr Connect       Date:  2022-04-29       Impact factor: 3.221

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.